Shandong Xinhua Pharmaceutical Co., Ltd

Hualu Network Group 中文版

Investor Relation

Information transparency and trust in peers

Investor Relation

INTERIM REPORT

Overseas Regulatory Announcement-Announcement on Lidocaine and Prilocaine Cream having obtained Drug Registration Certificate

Overseas Regulatory Announcement-Announcement on Vonoprazan Fumarate having obtained the Notification of Approval of Marketing Application for Chemical Active Pharmaceutical Ingredients

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2025

Overseas Regulatory Announcement-Announcement on Having Obtained the Drug Registration Certificate and Other Relevant Information

Articles of Association

Articles of Association

Poll Results of the Extraordinary General Meeting

Poll Results of the Extraordinary General Meeting

Renewal of Continuing Connected Transaction In Relation To Trademark Licence Agreement

Renewal of Continuing Connected Transaction In Relation To Trademark Licence Agreement

Overseas Regulatory Announcement-Announcement on Bisoprolol Fumarate Tablets Having Obtained Drug Registration Certificate

Announcement Notice of Board Meeting

Reply Slip for the First Extraordinary General Meeting for the Year 2025

总条数: 79条

＜ 1 ... 4 5 6 ... 8 ＞

跳转到: 页